QLGN · Qualigen Therapeutics Inc

-

Please sign in to comment on QLGN

1 Comment

Admin

4 years, 12 months ago

Qualigen Therapeutics, Inc is currently in a long term downtrend where the price is trading 37.4% below its 200 day moving average.

From a valuation standpoint, the stock is 99.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 12.9.

Qualigen Therapeutics, Inc's total revenue sank by 30.3% to $838K since the same quarter in the previous year.

Its net income has dropped by 1723.6% to $-8M since the same quarter in the previous year.

Finally, its free cash flow fell by 107.4% to $-3M since the same quarter in the previous year.

Based on the above factors, Qualigen Therapeutics, Inc gets an overall score of 1/5.

Exchange	NASDAQ
CurrencyCode	USD
ISIN	US74754R1032
Sector	Healthcare
Industry	Biotechnology

Market Cap	7M
PE Ratio	1.13
Target Price	5
Beta	0.28
Dividend Yield	None

ABOUT

Qualigen Therapeutics Inc

Qualigen Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of treatments for adult and pediatric cancer. The company's lead program is QN-302, an investigational small molecule G-quadruplexes (G4)-selective transcription inhibitor, which is in Phase I clinical trial for the treatment of pancreatic cancer and other solid tumors. It is also developing Pan-RAS that is in preclinical stage for the treatment of advanced solid tumors. The company was founded in 1996 and is based in Carlsbad, California.

QLGN · Qualigen Therapeutics Inc

-

Qualigen Therapeutics Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Qualigen Therapeutics Inc using a moving average strategy